Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability.
Saved in:
| Title: | Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability. |
|---|---|
| Authors: | Simpson, Seth (AUTHOR), Dominick, Kelli C. (AUTHOR), Erickson, Craig A. (AUTHOR), Lamy, Martine (AUTHOR) |
| Source: | Journal of Autism & Developmental Disorders. May2026, Vol. 56 Issue 5, p2077-2083. 7p. |
| Subjects: | Patient compliance, Disabilities, Bipolar disorder, Patient safety, Controlled release preparations, Body mass index, Data analysis, T-test (Statistics), Autism, Emergency room visits, Antipsychotic agents, Descriptive statistics, Deprescribing, Retrospective studies, Severity of illness index, Schizophrenia, Intellectual disabilities, Injections, Obsessive-compulsive disorder, Drug efficacy, Medical records, Acquisition of data, Statistics, Asperger's syndrome, Drugs, Affect (Psychology), Drug tolerance, Transition to adulthood, Carpal tunnel syndrome, Mental depression |
| Abstract: | This retrospective chart review examines the safety, tolerability and effectiveness of long acting injectable paliperidone palmitate (P-LAI) targeting irritability in twenty-six youth and transition-aged individuals with autism spectrum disorder (ASD) and/or intellectual disability (ID) over a 3-year window. Clinical response was evaluated via prospectively assigned Clinical Global Impressions Severity (CGI-S) and Improvement (CGI-I) scales as well as number of hospital presentations. P-LAI was well tolerated with only 3 patients stopping P-LAI due to side effects. The average duration of P-LAI treatment was 21.1 months. Difficulty with medication compliance was the most common reason for initiating P-LAI. There was a statistically significant improvement in CGI-I, CGI-S and hospital visits and no change in BMI noted. Given the potential difficulty of medication administration in this population, this evidence of safety, tolerability as well as preliminary data supporting effectiveness is an important addition to the literature regarding psychopharmacologic management of irritability in youth with ASD and ID. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Autism & Developmental Disorders is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | This retrospective chart review examines the safety, tolerability and effectiveness of long acting injectable paliperidone palmitate (P-LAI) targeting irritability in twenty-six youth and transition-aged individuals with autism spectrum disorder (ASD) and/or intellectual disability (ID) over a 3-year window. Clinical response was evaluated via prospectively assigned Clinical Global Impressions Severity (CGI-S) and Improvement (CGI-I) scales as well as number of hospital presentations. P-LAI was well tolerated with only 3 patients stopping P-LAI due to side effects. The average duration of P-LAI treatment was 21.1 months. Difficulty with medication compliance was the most common reason for initiating P-LAI. There was a statistically significant improvement in CGI-I, CGI-S and hospital visits and no change in BMI noted. Given the potential difficulty of medication administration in this population, this evidence of safety, tolerability as well as preliminary data supporting effectiveness is an important addition to the literature regarding psychopharmacologic management of irritability in youth with ASD and ID. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 01623257 |
| DOI: | 10.1007/s10803-024-06372-9 |
